Home
overview
Following on from the success of last year’s Superbugs & Superdrugs conference we are once again bringing together the international specialists within the antibiotics field and tackling the issues that matter. Superbugs & Superdrugs II offers the unique opportunity to hear from a leading international panel of speakers at the cutting edge of antimicrobial resistance. This event gives you the opportunity to strategically align your company for optimum success.

SPECIAL OFFER FOR PREMIUM USERS!

SMi Online would like to offer all Premium Users the opportunity to experience an SMi event first hand - and are offering complimentary places to the post conference interactive workshop - 'Cost Effective R&D', run in association with wci.

These complimentary places are strictly limited and are on a first come, first served basis. If you would like to reserve your place at 'Cost Effective R&D' please e-mail swatt@smiconferences.co.uk.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr André Bryskier

Dr André Bryskier, Head of Clinical Pharmacology, Anti Infectives, Hoechst Marion Roussel

9:10 SUPERBUGS: A GLOBAL PROBLEM

Prof Jan Verhoef

Prof Jan Verhoef, Professor of Clinical Microbiology, University Medical Center Utrecht

  • The global threat of antibiotic resistance, the need for new agents
  • Emerging problems of resistance against gram-positive bacteria
  • Emerging problems of resistance against gram-negative bacteria
  • Acquiring resistance against gram-negative bacteria
  • Potential ways of dealing with resistant gram-negative bacteria
  • Implications of resistant gram-negative bacteria for patient outcomes in hospitals
  • 9:40 A PHARMACEUTICAL PERSPECTIVE

    Dr Jeffrey R Edwards

    Dr Jeffrey R Edwards, Director, Clinical Microbiology, Infection Therapy Area, AstraZeneca

  • Why develop a new anti infective agent?
  • The infrastructure required, competition for resources
  • What new agents are needed?
  • Something really new, another variant or a ‘compound too far’
  • Discovery, development and commercialisation
  • 10:20 DEVELOPING A GLYCYLCYCLINE WITH A BROAD SPECTRUM OF ACTIVITY

    Dr Steven J Projan

    Dr Steven J Projan, Director, Antibacterial Research, Wyeth Ayerst Research

  • Targeting gram positive, gram-negative and atypical bacteria
  • Developing GAR-936, a novel glycylcycline
  • Mechanism of action of GAR-936
  • Taking GAR-936 into clinical trials
  • Safety and efficacy of GAR-936
  • Anticipating the future of glycylcycline
  • 11:00 Morning Coffee

    11:20 THERAPEUTIC OPTIONS FOR THE TREATMENT OF SERIOUS SYSTEMIC INFECTION IN HOSPITALISED PATIENTS

    Dr Richard J White

    Dr Richard J White, Chief Scientific Officer, Versicor

  • Using glycopeptides to defeat bacteria
  • Developing BI 397, a second generation glycopeptide
  • Mechanism of action of BI 397
  • Pharmacodynamics of BI 397
  • Taking BI 397 into clinical trials
  • Anticipating the future of glycopeptides
  • 12:00 STRUCTURE-BASED DISCOVERY OF ANTI-BACTERIALS

    Prof William Shaw

    Prof William Shaw, Chief Scientific Officer, PanTherix

  • Genomics to high resolution structures of validated targets
  • Use of structural information to assist chemical design
  • Virtual screening of large diverse libraries
  • Drug contact with conserved active site hinders ‘easy’ resistance
  • 12:40 Lunch

    13:40 DISCOVERY AND DEVELOPMENT OF A NEW QUINOLONE ANTIBIOTIC

    Prof Axel Dalhoff

    Prof Axel Dalhoff, Head, Preclinical Development Anti Infectives, Bayer

  • Its strategy for combating anti infective drug resistance
  • The development of quinolones
  • Mechanism of action of quinolones
  • Therapeutic target pathogens
  • Decreasing the rate of emergence of drug resistance
  • 14:20 THE NEW GENERATION OF QUINOLONES

    Dr John F Barrett

    Dr John F Barrett, Executive Director, Microbiology, Anti Infectives Discovery, Bristol-Myers Squibb

  • An overview of the evolution and class of quinolones
  • Developmental trends amongst quinolones
  • Advantages of quinolones over existing and alternative therapies
  • Unmet patients’ needs
  • Opportunities for quinolones
  • 15:00 OUTWITTING ANTIBIOTIC RESISTANT BACTERIA

    Dr George Miller

    Dr George Miller, Senior Vice President, Research & Development, Microcide Pharmaceuticals

  • Prolonging the usefulness of existing classes of antimicrobials
  • A cephalosporin for methicillin-resistant Staphylococcus - RWJ-54428
  • Inhibitors of bacterial and fungal efflux pumps
  • Developing new classes of antimicrobials using functional genomics - antibacterials and antifungals
  • 15:40 Afternoon Tea

    16:00 LESSONS FROM DAPTOMYCIN

    Dr Francis P Tally

    Dr Francis P Tally, Executive Vice President, Scientific Affairs, Cubist Pharmaceuticals

  • Developing daptomycin
  • Selecting the proper dose for an antibiotic
  • Rapid killing of a wide range of resistant strains
  • Pharmacokinetic separation of efficacy and toxicity
  • Review clinical data
  • 16:30 UTILISING PHARMACODYNAMICS IN CLINICAL DEVELOPMENT

    Dr Paul Ambrose

    Dr Paul Ambrose, Therapeutic Director, Infectious Diseases, Kendle International

  • Pharmacodynamic parameters and target development
  • Dose and regimen selection
  • Human trials
  • Susceptibility break point determination
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    17:40 Drinks Reception for Delegates and Speakers

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr George Shimer

    Dr George Shimer, Vice President, Biology, Cubist Pharmaceuticals

    9:10 INNOVATIONS IN SURVEILLANCE: COMBINING INFORMATION TECHNOLOGY AND MICROBIOLOGY FOR SCIENCE AND INDUSTRY

    Dr Daniel F Sahm

    Dr Daniel F Sahm, Chief Scientific Officer, MRL Pharmaceutical Services

  • Surveillance for science and industry - needs and roles
  • Implementing state-of-the-art information technology for electronic surveillance. Precision and quality is everything
  • Electronic surveillance in support of antimicrobial development
  • Maximising output of centralised in vitro susceptibility testing
  • Innovations in surveillance for infectious disease - beyond resistance
  • 9:40 THE IMPACT OF BIOINFORMATICS ON THE DISCOVERY OF NEW ANTIBIOTICS

    Dr Georg Casari

    Dr Georg Casari, Vice President, Bioinformatics, LION Bioscience

  • Impact of bioinformatics on the discovery process
  • Extracting the maximum value from experimental data
  • Discrimination of targets employing in silico methods
  • Text mining for retrieval of higher order sequence information
  • Anticipating the future of bioinformatics in the field of antimicrobials
  • 10:20 ENHANCING ANTI INFECTIVES DISCOVERY

    Dr Ronnie Farquhar

    Dr Ronnie Farquhar, Senior Programme Director, Anti Infectives, Millennium Pharmaceuticals

  • Lessons learned from employing large scale genetics and genomics in conducting the discovery of antibacterial and antifungal drug targets
  • Application of high throughput screening, automation and informatics towards drug candidate identification: from black box to defined target screening and back again
  • The benefits of strategic alliances
  • 11:00 Morning Coffee

    11:20 INTEGRATING BACTERIAL GENOMIC INFORMATION

    Dr Hannes Loferer

    Dr Hannes Loferer, Head, Microbiology, GPC

  • Comparative genomics and novel targets
  • Assay development strategies
  • Functional genomics, interaction technologies and compound mode-of-action studies
  • Establishing drug discovery collaborations
  • 12:00 ANTI INFECTIVE DRUGS BASED ON THE QUORUM SYSTEM

    Dr Jeffrey Stein

    Dr Jeffrey Stein, Vice President, Chief Scientific Officer, Quorex Pharmaceuticals

  • A novel gene pathway occurring in a wide variety of bacteria
  • Governing the onset of bacterial pathogenesis in a host
  • Finding a new regulatory molecule and signalling system that mediates communication amongst bacterial cells
  • Developing a signalling pathway and a screening platform for novel anti bacterials
  • Decreased likelihood of evolving resistance mechanisms
  • 12:40 Lunch

    13:40 UTILISING THE PNA TECHNOLOGY FOR THE DISCOVERY OF ANTI INFECTIVES

    Dr Carsten Schou

    Dr Carsten Schou, Vice President, Research, Pantheco

  • PNA, a new chemical entity
  • Binding to single-stranded nucleic acids
  • Developing anti bacterial drugs based on PNA
  • Targeting selected bacterial genome sequences for a PNA drug
  • Decreasing the rate of developing bacterial resistance
  • Anticipating the future of anti bacterial PNA based drugs
  • 14:20 FINDING NOVEL CLASSES OF ANTIMICROBIAL COMPOUNDS

    Dr Dana M Fowlkes

    Dr Dana M Fowlkes, Chairman and Chief Executive Officer, Novalon Pharmaceuticals

  • Identifying novel genomics-derived anti bacterial targets
  • Utilising Novalon’s advanced peptide aptamer technology (BioKey™)
  • Isolating surrogate ligands (BioKeys)
  • Developing high throughput screening assays (BioKey Assays)
  • Screening small molecule chemical libraries with BioKey Assays
  • Developing a new generation of broad-spectrum antibiotics;
    Impact of Novalon’s BioKey technology on targets of unknown function
  • 15:00 INTRABIOTICS: HARNESSING NATURAL HOST DEFENCES

    Dr John C Fiddes

    Dr John C Fiddes, Vice President, Research & Development, IntraBiotics Pharmaceuticals

  • Role of antimicrobial peptides in innate immunity
  • The protegrin family of antimicrobial peptides
  • IB-367: a synthetic protegrin analog
  • Mechanism of action of IB-367
  • Phase II efficacy data of IB-367 Rinse to treat oral mucositis
  • 15:20 Afternoon Tea

    16:00 INHIBITING BACTERIAL ADHERENCE

    Dr Joseph M Patti

    Dr Joseph M Patti, Vice President, Preclinical Development, Chief Scientific Officer, Inhibitex

  • MSCRAMMs - microbial surface components recognising adhesive matrix molecules
  • MSCRAMMs - novel targets for immunotherapy
  • Polyclonal and monoclonal antibody product opportunities
  • Development of MSCRAMM based subunit vaccines
  • 16:30 ANTIMICROBIAL R&D - A VIEW FROM OUTSIDE BIG PHARMA

    Dr Richard Bax

    Dr Richard Bax, Development Director, Transcrip, Bax Consulting

  • How can companies optimise their early compounds?
  • Quickest route from compound selection to phase 2
  • What do you need to know?
  • What do you do need to know?
  • What interests big pharma?
  • How to optimise your proposal and increase the likelihood of getting a positive response from big pharma
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Cost Effective R&D
    Workshop

    Cost Effective R&D

    The Hatton, at etc. venues
    12th May 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.